Objective:

To systematically summarize current data on the pharmacological properties, clinical efficacy, and multidisciplinary applications of vardenafil in the treatment of erectile dysfunction (ED), highlighting its significance in improving patient outcomes.

Key Findings:

• Vardenafil shows a rapid onset of action and minimal food interactions, making it a viable first-line treatment for specific patient profiles. Combination therapies involving vardenafil consistently demonstrate greater improvements in erectile function compared to monotherapy, especially in patients with hypogonadism or psychological comorbidities, which can significantly enhance overall treatment satisfaction and quality of life. Vardenafil exhibits higher affinity for PDE5 compared to other PDE5 inhibitors, suggesting a more potent and sustained effect.

Interpretation:

The review highlights the importance of a multidisciplinary approach to ED treatment, integrating vardenafil with endocrine, psychological, and lifestyle interventions to enhance patient outcomes and improve quality of life.

Limitations:

• The review is based on a narrative synthesis due to substantial heterogeneity in study designs and outcome measures, which may limit the generalizability of findings. The evidence supporting vardenafil's integration within a multidisciplinary framework remains fragmented and inconsistent, necessitating further research.

Conclusion:

Vardenafil is an effective component of a comprehensive treatment strategy for ED, particularly when used in combination with other therapeutic modalities, emphasizing the need for a multidisciplinary approach to optimize patient outcomes.